Krystal Biotech Announces Positive Phase 1 KB407 Data for Cystic Fibrosis, Confirming CFTR Delivery and Advancing to Registrational Study

summarizeSummary

Krystal Biotech reported positive interim Phase 1 clinical data for KB407 in cystic fibrosis, demonstrating successful wild-type CFTR gene delivery and expression in patient lungs, paving the way for a registrational repeat dosing study.

check_boxKey Events

• Positive Phase 1 Clinical Data

  Interim results from the highest dose cohort of the CORAL-1 study for KB407 in cystic fibrosis patients showed successful lung delivery and expression of wild-type CFTR protein.

• Molecular Confirmation of Gene Delivery

  Wild-type CFTR delivery and expression were confirmed in conducting airway cells, with transduction rates ranging from 29.4% to 42.1% across six patients, irrespective of modulator status or genetic background.

• Advancement to Registrational Study

  The company has submitted the design for CORAL-3, a registrational repeat dosing study, to the FDA and anticipates starting enrollment in the first half of 2026.

• Well-Tolerated Safety Profile

  KB407 continued to be well tolerated in the highest dose cohort, with adverse events being mild-to-moderate and transient, and one serious adverse event deemed procedure-related.

auto_awesomeAnalysis

This 8-K filing details a highly significant clinical milestone for Krystal Biotech's KB407 program. The confirmation of wild-type CFTR gene delivery and expression in the lungs of cystic fibrosis patients, including those with class I mutations ineligible for current modulator therapies, represents a major de-risking event for this gene therapy. The high transduction rates (29.4% to 42.1% of conducting airway cells) and broad distribution across patient airways are particularly encouraging. The company's immediate plan to advance to a registrational repeat dosing study (CORAL-3) with FDA alignment expected in Q1 2026 and enrollment in Q2 2026 underscores the confidence in the data and the potential for KB407 to address a significant unmet medical need. This positive update could substantially enhance the long-term value proposition for Krystal Biotech, especially given the potential $2B+ market opportunity in modulator-ineligible or refractory CF patients.